Cardiologia Croatica, Vol. 9 No. 7-8, 2014.
Stručni rad
https://doi.org/10.15836/ccar.2014.320
Clinical Evidence of the Efficacy of Krka’s Rosuvastatin in the Treatment of Hyperlipidemia with Focus on Additional Dosage Strengths.
Sanja Brus
; Krka, d. d., Novo mesto, Slovenia
Breda Barbič-Žagar
orcid.org/0000-0002-1173-7361
; Krka, d. d., Novo mesto, Slovenia
Sažetak
Dyslipidemia is associated with the highest population attributable risk for cardiovascular disease. Of various cardiovascular preventive therapies, the evidence from randomised controlled studies supporting the importance of aggressive lipid lowering is the most robust for statins. Clinical studies have shown that even a small reduction of LDL cholesterol has an important clinical effect. However, despite clear evidence of the benefits of statin therapy, these drugs are still underused or underdosed. The majority of patients with dyslipidemia are treated with the lowest doses, and doctors use the highest doses only very rarely. To help close the therapeutic gap, Krka has made available a wide range of rosuvastatin dosage strengths, including two intermediate strengths of 15 mg and 30 mg. These enable treatment to be individually adjusted and result in more patients reaching target
lipid levels.
Ključne riječi
rosuvastatin; dosage strengths; LDL cholesterol; cardiovascular disease
Hrčak ID:
141146
URI
Datum izdavanja:
5.9.2014.
Posjeta: 1.311 *